Amanote Research
Register
Sign In
P2.01-03 Quality of Life Outcomes for FDA-Approved Agents in Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.1057
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
H. Albaba
A. Bezjak
N. Leighl
Publisher
Elsevier BV
Related search
P2.01-131 Apatinib as an Alternative for Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Quality of Life in Patients With Non-Small Cell Lung Cancer
Vojnosanitetski Pregled
Medicine
Pharmacology
P2.01-117 Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.01-50 Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Cost Effectiveness of Treatment With New Agents in Advanced Non-Small-Cell Lung Cancer
PharmacoEconomics
Health Policy
Public Health
Occupational Health
Pharmacology
Environmental
P2.01-49 Comparision of Radiotheraphy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.01-29 Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Health Related Quality of Life Among Patients Diagnosed With Advanced Non Small Cell Lung Cancer in India
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
P2.01-96 Dysgeusia Associated With Nutritional and Quality of Life Parameters in Non-Small Cell Lung Cancer Patients Naïve to Chemotherapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
